IDiyas

For the Inventor, By the Inventor

Peabody, MA, United States of America

Scott Louis Cohen

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 15(Granted Patents)


Location History:

  • Cambridge, MA (US) (2014)
  • Peabody, MA (US) (2012 - 2020)
  • Burlington, MA (US) (2022)

Company Filing History:

goldMedal11 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2012-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11466048 - 3' end caps, 5′ end caps and combinations thereof for therapeutic RNA (2022-10-11),
2. 10676499 - 3' end caps, 5′ end caps and combinations thereof for therapeutic RNA (2020-06-09),
3. 10112963 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2018-10-30),
4. 9789118 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2017-10-17),
5. 9498483 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2016-11-22),
6. 9480693 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2016-11-01),
7. 9163040 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2015-10-20),
8. 9040690 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2015-05-26),
9. 8697739 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2014-04-15),
10. 8394858 - Cyclohexane derivatives and uses thereof (2013-03-12),
11. 8324239 - Furopyridine compounds and uses thereof (2012-12-04),

Title: Scott Louis Cohen: Innovator in Therapeutic RNA Modifications

Introduction

Scott Louis Cohen is a prominent inventor based in Peabody, MA (US). He has made significant contributions to the field of therapeutic RNA through his innovative work. With a total of 11 patents to his name, Cohen has established himself as a key figure in the development of modified nucleic acids.

Latest Patents

Cohen's latest patents include advancements in 3' end caps, 5' end caps, and combinations thereof for therapeutic RNA. These disclosures relate to nucleic acids that contain modifications at the 5'-end, 3'-end, or both. The compounds developed can be used to create modified nucleic acids that exhibit improved expression, lower immunogenicity, and enhanced stability compared to their unmodified counterparts.

Career Highlights

Scott Louis Cohen is currently associated with Novartis AG, where he continues to push the boundaries of innovation in the pharmaceutical industry. His work focuses on enhancing the efficacy of therapeutic RNA, which has the potential to revolutionize treatment options for various diseases.

Collaborations

Cohen collaborates with notable colleagues such as David Weninger Barnes and Gregory Raymond Bebernitz. These partnerships contribute to the advancement of research and development in the field of therapeutic RNA.

Conclusion

Scott Louis Cohen's contributions to the field of therapeutic RNA through his innovative patents and collaborations highlight his importance as an inventor. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…